In a nutshell This trial will evaluate a molecular test, EndoPredict®, in the treatment of breast cancer. The main outcome will be the adherence rate to EndoPredict® results. This trial is recruiting in South Carolina, USA. It is sponsored by Myriad Genetic Laboratories. The details Adjuvant chemotherapy (ACT) is...
Read MoreHormone receptor status-Positive (ER and/or PR) Posts on Medivizor
Standard adjuvant chemotherapy versus capecitabine: longer follow up results in older breast cancer patients
In a nutshell This study aimed to investigate the outcomes of standard adjuvant chemotherapy versus capecitabine (Xeloda) in older patients with breast cancer after 10 years. This study concluded that with longer follow up, outcomes remained superior with standard adjuvant chemotherapy. Some...
Read MoreHow effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?
In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations. Some background Breast cancer (BC) types can be...
Read MoreEndoPredict – can this prognostic test predict treatment success in breast cancer?
In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC. Some background Breast cancer (BC) is one of the most common cancers. BC treatment...
Read MoreEvaluating palbociclib for patients with previously treated breast cancer
In a nutshell This study evaluated how well palbociclib (Ibrance) works in patients with breast cancer who received multiple lines of previous therapy. This study found that palbociclib was effective for these patients. Some background There are several different treatments for breast cancer depending on the types of...
Read MoreDenosumab treatment in HR+ breast cancer
In a nutshell This study wanted to find out if adding the medication denosumab (Prolia, Xgeva) to cancer treatment for women with breast cancer reduces the risk of bone fractures. The study found that the patients treated with denosumab survived better, but there was no significant difference in the number of bone fractures. Some background Breast...
Read MoreEvaluating the effects of endocrine therapy in older women with breast cancer
In a nutshell This study investigated whether endocrine therapy affects memory in older women with breast cancer. This study concluded that endocrine therapy had a negative effect on these patients' memory, especially on verbal memory (memory related to words). Some background Some types of breast cancer can be treated using endocrine...
Read MorePalbociclib, ribociclib, and abemaciclib in treating breast cancer
In a nutshell This study wanted to find out which of three medicines was best for treating breast cancer, palbociclib (Ibrance), ribociclib (Kisquali), or abemaciclib (Verzenio). The study found that the medications all worked equally as well, but there were different side effects for each one. Some background Estrogen receptor positive (ER+) breast...
Read MoreRisk of blood clots in breast cancer patients treated with aromatase inhibitors or tamoxifen
In a nutshell This study wanted to find out if the risk of patients with breast cancer developing a blood clot was higher if they were treated with aromatase inhibitors, or tamoxifen (Nolvadex). The study found that the patients treated with tamoxifen had a higher risk of developing blood clots compared to those treated with aromatase...
Read MoreEverolimus and exemestane treatment in elderly patients with advanced breast cancer
In a nutshell This study wanted to analyse how treatment with everolimus (Afintor) and exemestane (Aromasin) is performed in patients with breast cancer, and if there are any side effects. The study found that treatment occured for an average of 28 .5 weeks, and side effects were seen in a number of patients, including...
Read MoreJoint pain and falls among women with breast cancer on aromatase inhibitors.
In a nutshell This study wanted to find out if joint pain is associated with falling down in patients with breast cancer who were treated with aromatase inhibitors. The study found that the patients who reported having joint pain were more likely to have a fall than those who had no joint pain. Some background Aromatase inhibitors are medications...
Read MoreJoint pain management in obese breast cancer patients treated with aromatase inhibitors
In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese. Some background...
Read More
